Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with poor prognosis. Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with IPF. These drugs reduce the rate of decline in forced vital capacity (FVC). Serum surfactant protein (SP)-A, SP-D...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Takumi, Otsuka, Mitsuo, Chiba, Hirofumi, Ikeda, Kimiyuki, Mori, Yuki, Umeda, Yasuaki, Nishikiori, Hirotaka, Kuronuma, Koji, Takahashi, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995128/
https://www.ncbi.nlm.nih.gov/pubmed/32005219
http://dx.doi.org/10.1186/s12890-020-1060-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995128/
https://www.ncbi.nlm.nih.gov/pubmed/32005219
http://dx.doi.org/10.1186/s12890-020-1060-y

Ejemplares similares